Calliditas Year-end report, January – December 2023
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX) 2023: Full approval for TARPEYO in the US; a year of successesOCTOBER – JANUARY – DECEMBER 2023(COMPARED TO JANUARY –DECEMBER 2022)DECEMBER · Net sales amounted to SEK 1,206.9 million, of which TARPEYO2023(COMPARED net sales amounted to SEK 1,075.8 million, for the year endedTO OCTOBER – December 31, 2023. For the year ended December 31, 2022, netDECEMBER sales amounted to SEK 802.9 million, of which TARPEYO net sales2022) amounted to SEK 372.2 million. · Net salesamounted to ·